Investigators carried out a high-throughput screen of the ReFRAME repurposing collection, which consolidates 14,095 molecules from multiple databases, to search for compounds active against both replicating and semidormant forms of Toxoplasma. The team engineered a permissive cyst-forming parasite strain, Tg68, to express two orthogonal luciferase reporters: nano luciferase under the pBAG1 promoter to monitor bradyzoite growth, and firefly luciferase under the pTub1 promoter to track tachyzoite growth. Screening was performed in a 384-well format and used single-concentration profiling at 10 micromolar. From that primary screen, 160 compounds produced greater than 80% inhibition of both parasite stages at the tested concentration.
The dual-reporter approach enabled parallel readouts of acute and chronic-stage biology in the same screening cascade. The authors reported the assay design and hit definition as central to selecting compounds with cross-stage activity, and they emphasized the need to triage hits for host-cell toxicity before follow-up.
After the primary hit list was generated, data from a publicly available HEK293T cytotoxicity dataset were used to remove likely host-toxic compounds. Sixty-one compounds flagged with half-maximal cytotoxicity (CC50) below 5 micromolar were excluded, leaving 99 candidates for further evaluation. From that narrowed set, the investigators selected 15 top hits based on potency and a selectivity index (CC50:EC50) threshold relative to HepG2 cells; the source reports a cutoff of SI greater than 20 for this prioritization.
The preprint documents follow-up profiling of these top candidates across in vitro growth assays for tachyzoites and bradyzoites, and also against ex vivo liberated and intact tissue cysts. The report does not provide in vivo efficacy data, nor does it give detailed dosing regimens for animal work — the authors explicitly identify in vivo evaluation and host-toxicity liabilities as subsequent steps.
Several prioritized compounds stood out in assays using intact cysts. The authors reported that marizomib, monensin, narasin, and LY2090314 produced the strongest inhibition following 24-hour treatment of intact cyst preparations. These findings indicate activity in an ex vivo cyst context, which differs from standard tachyzoite assays and targets a clinically relevant semidormant stage.
The team also tested top hits in combination with established clinical agents for toxoplasmosis, specifically atovaquone and pyrimethamine. Combination testing in the assays described yielded primarily additive interactions between the repurposed hits and the clinical compounds. The preprint does not provide full combination index matrices or in vivo combination data; investigators noted these combination results as part of early characterization.
Resistance potential was addressed using minimum inoculum of resistance (MIR) assays. The source reports that, of nine compounds tested in MIR assays, six produced no detectable parasite recovery over a 30-day period, suggesting a low propensity for resistance under those experimental conditions. By contrast, populations selected with LY2090314 developed substantial resistance, with the authors reporting a 26- to 29-fold shift in sensitivity in the resistant lines.
Genetic analysis of LY2090314-resistant populations identified a mutation in a parasite kinase: TgGSK3 L53V. The authors presented this variant as a candidate resistance determinant associated with the LY2090314-resistant phenotype. The report does not state whether this mutation alone is sufficient to confer resistance, nor does it describe reverse-genetics validation; those remain open experimental questions according to the preprint.
This report is a preprint and has not been peer reviewed. The authors declared no competing interests. Key limitations documented in the source include the absence of in vivo efficacy and host-toxicity studies within the reported dataset. The manuscript does not provide detailed pharmacokinetic or dosing information for any compound in animal models, nor does it present comprehensive mechanistic validation for the top hits beyond the LY2090314 resistance-associated TgGSK3 L53V mutation.
The authors framed the prioritized compounds as starting points for deeper mechanistic investigation, expanded resistance mapping, and formal evaluation of in vivo efficacy and host toxicities. Those next steps — moving from ex vivo and in vitro activity to animal models and safety profiling — are explicitly identified in the preprint as required to assess translational potential.